# Abiomed

> Abiomed is a VC fund in Danvers backing Medical Device and Health Care. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Danvers, United States
- Total investments: 8
- Last investment: May 2022
- Lead investor: 63%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/abiomed
- X (Twitter): https://www.twitter.com/abiomedimpella
- Website: http://abiomed.com
- Facebook: https://www.facebook.com/abiomed

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's productsare used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

## Contacts

5 contacts available for Abiomed. Shizune tracks 5 team members at Abiomed. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/abiomed?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 7 | 88% |
| Health Care | 6 | 75% |
| Medical | 4 | 50% |
| Biotechnology | 2 | 25% |
| Hospital | 1 | 13% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 25% |
| Series D | 2 | 25% |
| Series A | 1 | 13% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 50% |
| Germany | 2 | 25% |
| Israel | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chuck Simonton | Chief Medical Officer, Vice President of Global Clinical & Medical Affairs | 0 | https://shizune.co/investors/profile/chuck-simonton |
| David Lederman | Founder | 0 | https://shizune.co/investors/profile/david-lederman |
| Noam Josephy | Director of Academic Research | 0 | https://shizune.co/investors/profile/noam-josephy |
| Ryan Orizondo | Senior Mechanical Engineer II | 0 | https://shizune.co/investors/profile/ryan-orizondo |
| Thorsten Siess | CTO | 1 | https://shizune.co/investors/profile/thorsten-siess |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Impulse Dynamics | Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $101M | Venture - Series Unknown | May 12, 2022 |  |
| Impulse Dynamics | Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $80.3M | Series D | Dec 03, 2019 |  |
| Shockwave Medical | Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularizationtechnologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR. | $15M | Series D | Dec 06, 2018 |  |
| Protembis | ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation. | $10M | Series A | Sep 13, 2018 |  |
| RenalGuard Solutions | Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness atpreventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. | $7M | Series B | Sep 13, 2018 |  |
| Reprieve Cardiovascular | Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enableimproved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. | $7M |  | Sep 12, 2018 |  |
| Magenta Medical | Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure. | $15M | Series B | Sep 28, 2017 |  |
| ALung Technologies | ALung Technologies is a medical device manufacturing company that develops intracorporeal and extracorporeal gas exchange devices for the treatment of acute and chronic respiratory disorders. Its technology utilizes Hemolung, an extracorporeal gas exchange device that circulates blood through a small catheter; and Hattler Catheter, which is placedwithin the central venous bloodstream in the primary vein that returns blood to the heart and is inserted directly through the skin into the vein.The company was founded in 1997 and headquartered in Pittsburgh, Pennsylvania. | $36M | Series C | Apr 11, 2017 |  |

8 of 8 investments shown.

## Co-investors
- [Kennedy Lewis Investment Management](https://shizune.co/investors/profile/kennedy-lewis-investment-management) — VC Fund, 2 deals together
- [Accelerator Fund](https://shizune.co/investors/profile/accelerator-fund) — VC Fund, 1 deal together
- [Acorn](https://shizune.co/investors/profile/acorn) — VC Fund, 1 deal together
- [Alger](https://shizune.co/investors/profile/alger) — VC Fund, 1 deal together
- [Allos Ventures](https://shizune.co/investors/profile/allos-ventures) — VC Fund, 1 deal together
- [Amzak Health Investors](https://shizune.co/investors/profile/amzak-health-investors) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Medical Device Investors in Germany](https://shizune.co/investors/medical-device-investors-germany)
- [Medical Device VC Funds in Germany](https://shizune.co/investors/medical-device-vc-funds-germany)

## FAQ

### What does Abiomed invest in?

Abiomed invests primarily in Medical Device, Health Care and Medical startups, most often at Series B and Series D stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Abiomed?

Public channels for Abiomed include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Abiomed?

The team at Abiomed includes Chuck Simonton (Chief Medical Officer, Vice President of Global Clinical & Medical Affairs), David Lederman (Founder) and Noam Josephy (Director of Academic Research). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co